Cargando…

Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey

BACKGROUND & OBJECTIVES: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 C...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Sukhpal, Singh, Ajay, Saini, Sushma, Rohilla, Latika, Kaur, Jasvir, Chandi, Anadeep, Kaur, Gurpreet, Singh, Manjeet, Kumar, Pramod, Soni, Shiv Lal, Kajal, Kamal, Naik, Naveen B., Malhotra, Pankaj, Verma, Sanjay, Gupta, Madhu, Devnani, Mahesh, Das, Karobi, Pandav, S.S., Puri, G.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552383/
https://www.ncbi.nlm.nih.gov/pubmed/35859438
http://dx.doi.org/10.4103/ijmr.ijmr_1221_21
_version_ 1784806238679203840
author Kaur, Sukhpal
Singh, Ajay
Saini, Sushma
Rohilla, Latika
Kaur, Jasvir
Chandi, Anadeep
Kaur, Gurpreet
Singh, Manjeet
Kumar, Pramod
Soni, Shiv Lal
Kajal, Kamal
Naik, Naveen B.
Malhotra, Pankaj
Verma, Sanjay
Gupta, Madhu
Devnani, Mahesh
Das, Karobi
Pandav, S.S.
Puri, G.D.
author_facet Kaur, Sukhpal
Singh, Ajay
Saini, Sushma
Rohilla, Latika
Kaur, Jasvir
Chandi, Anadeep
Kaur, Gurpreet
Singh, Manjeet
Kumar, Pramod
Soni, Shiv Lal
Kajal, Kamal
Naik, Naveen B.
Malhotra, Pankaj
Verma, Sanjay
Gupta, Madhu
Devnani, Mahesh
Das, Karobi
Pandav, S.S.
Puri, G.D.
author_sort Kaur, Sukhpal
collection PubMed
description BACKGROUND & OBJECTIVES: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. METHODS: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. RESULTS: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 ±11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. INTERPRETATION & CONCLUSIONS: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.
format Online
Article
Text
id pubmed-9552383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-95523832022-10-12 Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey Kaur, Sukhpal Singh, Ajay Saini, Sushma Rohilla, Latika Kaur, Jasvir Chandi, Anadeep Kaur, Gurpreet Singh, Manjeet Kumar, Pramod Soni, Shiv Lal Kajal, Kamal Naik, Naveen B. Malhotra, Pankaj Verma, Sanjay Gupta, Madhu Devnani, Mahesh Das, Karobi Pandav, S.S. Puri, G.D. Indian J Med Res Original Article BACKGROUND & OBJECTIVES: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. METHODS: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. RESULTS: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 ±11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. INTERPRETATION & CONCLUSIONS: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization. Wolters Kluwer - Medknow 2022-01 /pmc/articles/PMC9552383/ /pubmed/35859438 http://dx.doi.org/10.4103/ijmr.ijmr_1221_21 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kaur, Sukhpal
Singh, Ajay
Saini, Sushma
Rohilla, Latika
Kaur, Jasvir
Chandi, Anadeep
Kaur, Gurpreet
Singh, Manjeet
Kumar, Pramod
Soni, Shiv Lal
Kajal, Kamal
Naik, Naveen B.
Malhotra, Pankaj
Verma, Sanjay
Gupta, Madhu
Devnani, Mahesh
Das, Karobi
Pandav, S.S.
Puri, G.D.
Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title_full Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title_fullStr Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title_full_unstemmed Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title_short Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
title_sort reporting adverse events of chadox1 ncov-19 coronavirus vaccine (recombinant) among the vaccinated healthcare professionals: a cross-sectional survey
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552383/
https://www.ncbi.nlm.nih.gov/pubmed/35859438
http://dx.doi.org/10.4103/ijmr.ijmr_1221_21
work_keys_str_mv AT kaursukhpal reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT singhajay reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT sainisushma reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT rohillalatika reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT kaurjasvir reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT chandianadeep reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT kaurgurpreet reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT singhmanjeet reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT kumarpramod reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT sonishivlal reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT kajalkamal reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT naiknaveenb reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT malhotrapankaj reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT vermasanjay reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT guptamadhu reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT devnanimahesh reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT daskarobi reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT pandavss reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey
AT purigd reportingadverseeventsofchadox1ncov19coronavirusvaccinerecombinantamongthevaccinatedhealthcareprofessionalsacrosssectionalsurvey